Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (13)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Pérez-Trallero, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pérez-Trallero, E.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy (2000) 45, 401-402
© 2000 The British Society for Antimicrobial Chemotherapy

Correspondence

Pneumococcal macrolide resistance—not a myth

Emilio Pérez-Trallero

Servicio de Microbiología, Complejo Hospitalario Donostia, Apartado 477, 20080 San Sebastiàn, Spain

Sir,

In an article appearing in a recent issue of the Journal,1 Amsden attempted to ‘demythologize’ the significance of pneumococcal resistance to macrolide antibiotics. He suggested that patients with infections caused by strains of Streptococcus pneumoniae resistant to these antibiotics could be treated successfully with azithromycin and perhaps other macrolides. He regrets that ‘As a result of these in vitro reports, many prescribers are changing their choice of antibiotics for pneumococcal, as well as for community-acquired respiratory tract infections in general, away from macrolides.' I believe . . . [Full Text of this Article]

Notes

References


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 ThoraxHome page
W S Lim, S V Baudouin, R C George, A T Hill, C Jamieson, I Le Jeune, J T Macfarlane, R C Read, H J Roberts, M L Levy, et al.
BTS guidelines for the management of community acquired pneumonia in adults: update 2009
Thorax, October 1, 2009; 64(Suppl_3): iii1 - iii55.
[Full Text] [PDF]

Home page
 Clin. Microbiol. Rev.Home page
M. A. Pfaller and D. J. Diekema
Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem
Clin. Microbiol. Rev., January 1, 2007; 20(1): 133 - 163.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
M. A. Pfaller, S. A. Messer, L. Boyken, H. Huynh, R. J. Hollis, and D. J. Diekema
In Vitro Activities of 5-Fluorocytosine against 8,803 Clinical Isolates of Candida spp.: Global Assessment of Primary Resistance Using National Committee for Clinical Laboratory Standards Susceptibility Testing Methods
Antimicrob. Agents Chemother., November 1, 2002; 46(11): 3518 - 3521.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
BTS Guidelines for the Management of Community Acquired Pneumonia in Adults
Thorax, December 1, 2001; 56(90004): iv1 - 64.
[Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
A. Bonnefoy, M. Guitton, C. Delachaume, P. Le Priol, and A.-M. Girard
In Vivo Efficacy of the New Ketolide Telithromycin (HMR 3647) in Murine Infection Models
Antimicrob. Agents Chemother., June 1, 2001; 45(6): 1688 - 1692.
[Abstract] [Full Text]